Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM

Inclusion Criteria: * Patients ≥ 18 and ≤75 years with type 1 diabetes; * Diagnosed as T1DM ≥ 12 months before enrollment in the study; * HbA1c ≥ 7.0 to ≤10.0%; * Receipt of basal plus pre-prandial insulin and/or oral anti-diabetic agents ≥ 12 weeks before enrollment in the study; * BMI ≤ 35kg / m2. Exclusion Criteria: * Patients with any of the following conditions will be excluded: * Pregnant or lactating women * Severe hypoglycemia within one month; * Myocardial infarction, stroke or other severe cardiovascular events within 6 months prior to informed consent * Receipt of Sulfonylureas, Meglitinides derivatives, Thiazolidinediones, Dpp-4 inhibitors or GLP-1 agonists within 3 months prior to informed consent; * Current treatment with systemic steroids or immunosuppressive agents, or have immunologic deficiency disease at time of informed consent * Severe mental instability, or alcohol abuse, or drug abuse * Cancer within 5 years prior to informed consent * Pancreatitis of severe infectious diseases within 1 months prior to informed consent * Known hypersensitivity or allergy to the insulin * Renal impairment (CKD-EPI eGFR\<60ml/min) * Impaired hepatic function, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined * Participation in another trial within 2 months prior to informed consent * Patients that investigators believe may fail to complete the study